Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wishbone Biotech has developed and commercialized W-Bone, a next-generation xenograft bone substitute derived from bovine hydroxyapatite. Their patented process removes all proteins—including prions—while preserving the natural micro/nano-topography of native bone, enhancing osteoconductivity and mineralization. The product meets ISO 13485 standards and US FDA guidelines. No specific clinical trial results are published, but the technology is positioned as superior to existing alternatives.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wishbone Biotech.